{
    "clinical_study": {
        "@rank": "63901", 
        "arm_group": {
            "arm_group_label": "Panitumumab 6 mg/kg", 
            "description": "Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks"
        }, 
        "brief_summary": {
            "textblock": "The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be\n      studied.\n\n      Specifically, information will be collected on the following as events of interest: skin\n      disorders, interstitial lung disease, infusion reactions, electrolyte abnormalities, and\n      cardiac disorders."
        }, 
        "brief_title": "Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance \"Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene\" (All-patient Surveillance)", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": "Advanced or Recurrent Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be\n      studied.\n\n      Participants of this surveillance will be patients with unresectable, advanced or recurrent\n      colorectal cancer with the wild-type KRAS gene. The planned sample size is 2,000 patients.\n\n      The usual adult dosage is 6 mg/kg of panitumumab  given by intravenous drip infusion over a\n      60-minute period once every 2 weeks. The dosage may also be reduced as needed, depending on\n      the patient's condition."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Unresectable, advanced or recurrent colorectal cancer with wild-type KRAS gene\n\n        Exclusion Criteria:\n\n          -  Patients with a medical history of severe hypersensitivity to any of the ingredients\n             of Vectibix"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Unresectable, advanced or recurrent colorectal cancer with wild-type KRAS gene"
            }
        }, 
        "enrollment": {
            "#text": "3091", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089737", 
            "org_study_id": "183-011"
        }, 
        "intervention": {
            "arm_group_label": "Panitumumab 6 mg/kg", 
            "description": "Panitumumab  for intravenous infusion", 
            "intervention_name": "Panitumumab", 
            "intervention_type": "Drug", 
            "other_name": "Vectibix"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2014", 
        "number_of_groups": "1", 
        "official_title": "Vectibix for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance \"Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene\" (All-patient Surveillance)", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The frequency of adverse drug reactions  by type, seriousness and time to onset. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline through Week 42"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089737"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The time to progression from the start of panitumumab administration will be tabulated.", 
                "measure": "Existence or non-existence of progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Week 42"
            }, 
            {
                "description": "The time to death from the start of panitumumab administration will be tabulated.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Week 42"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}